ITM2A and breast cancer: The AE (for Nm, ERm and AE: p <  0.0001, HR = 0.75, 95% CI = 0.68–0.82) and MR (for Nm, ERm and MR: p <  0.0001, HR = 0.70, 95% CI = 0.62–0.80) data indicated that low ITM2A expression is associated with poor prognosis for breast cancer.